Skip to main content

Table 2 Cross-resistance of HMECd1 and HMECd2

From: Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy

  IC50 μg/ml (RI)
HMEC-1 HMECd1 HMECd2
Doxorubicin 0.0028 ± 0.0003 (1) 0.1 ± 0.027 (35.7) * 0.5 ± 0.01 (178.5) *
Daunorubicin 0.018 ± 0.009 (1) 0.92 ± 0.01 (51.1) * 1.7 ± 0.78 (94.4) *
Vinblastine 0.023 ± 0.007 (1) 0.16 ± 0.03 (69.5) * 0.2 ± 0.03 (86.9) *
Etoposide 0.0031 ± 0.0006 (1) 0.062 ± 0.0062 (20) * 0.6 ± 0.094 (203.5) *
Mytomycin C 0.16 ± 0.0074 (1) 0.15 ± 0.071 (0.9) 0.18 ± 0.0003 (1.1)
  1. The cells were cultured for 72 hours at 37°C in the presence of increasing concentrations of Dox, Etoposide, Daunorubicin, Mytomycin C, or Vinblastine, then incubated with 1 μCi 3H-thymidine/well for 1 hour at 37°C. The radioactivity incorporated into the cell was then measured. IC50 were determined over three separate experiments. Results are expressed as the mean ± SEM. *p <0.05 for statistical significance.